New drug duo aims to tame rare bone marrow cancers
NCT ID NCT07128381
First seen Jun 25, 2026 · Last updated Jul 16, 2026 · Updated 3 times
Summary
This study tests two drugs—axatilimab and ruxolitinib—together in people with myelofibrosis or chronic myelomonocytic leukemia. The goal is to find a safe dose and see if the combination helps control the disease. About 66 adults who have tried other treatments or are new to therapy will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- axatilimab and ruxolitinib
- What this could lead to
- If successful, this combination could offer a new treatment option to better control myelofibrosis and chronic myelomonocytic leukemia.
- What could go wrong
- This is an early-phase trial with only 66 participants, so results may not apply broadly. Side effects from the drug combination are possible and not yet fully known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Texas M. D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Action pill tame bone marrow tumors?
- Can a new daily pill shrink the spleen and ease myelofibrosis symptoms?
- New pill targets genetic weakness in Hard-to-Treat blood cancers
- New transplant recipe targets tough leukemia
- New combo therapy hopes to shrink spleens and ease symptoms in Tough-to-Treat myelofibrosis
- New drug aims to stop anemia after stem cell transplants